Highlights fourth quarter 2024:
o Q4 revenue reached USD 52.0 million, a 7% increase YoY, with adjusted EBITDA
of USD 7.4 million, up from USD 2.5 million last year.
o Full-year 2024 revenue totalled USD 199.0 million, up 1% YoY, while adjusted
EBITDA grew 29% to USD 29.0 million.
o Human Health Ingredients reported USD 25.5 million in revenue, a 25% increase
YoY, driven by strong growth across most regions. Adjusted EBITDA rose 31% YoY
to USD 9.6 million.
o Consumer Health Products generated USD 29.2 million in revenue, down 4% YoY,
but remained stable compared to Q3 2024.
o Emerging Business delivered USD 2.2 million in revenue, up 5% YoY, driven by
increased online sales. EBITDA loss narrowed to USD -1.1 million.
o The company implemented a restructuring and improvement program, with
completion planned during 2025

"We delivered a decent quarter, achieving 7% revenue growth and a significant
improvement in EBITDA compared to the same period last year. We are mostly proud
of the continued momentum in our Human Health Ingredients segment, which has now
delivered eight consecutive quarters of year-over-year revenue
growth-demonstrating the consistency we have built since launching our
turnaround program. Our core krill oil products have maintained strong
performance, averaging 25% annual growth since 2022.", said Matts Johansen, CEO
of Aker BioMarine.  

"2024 has held two different phases for Aker BioMarine. The first half of the
year focused on successfully completing the Feed Ingredients segment
transaction, while the second half has been dedicated to positioning the
remaining business for long-term growth. Immediately post the transaction, we
launched a restructuring and improvement program to enhance organizational,
operational, and financial efficiencies. I want to extend my gratitude to all
our employees for their dedication and hard work in making this possible.," he
concludes.

Outlook
Aker BioMarine remains focused on strengthening its core business and driving
sustainable growth. The Human Health Ingredients segment continues to build on a
solid foundation, positioning itself for further expansion, both geographically
and in product offering. Meanwhile, Consumer Health Products expect to return to
year-over-year revenue growth, reinforcing the segment's long-term potential.
The Emerging Business segment has made significant steps towards achieving cash
break-even, and will continue to do so in 2025. Additionally, the company will
implement organizational, operational, and financial efficiency from its
improvement and restructuring program.

Attached is the quarterly presentation for Q4. Group reported financial figures
can be downloaded in an excel from the company's investor page: Investor -
Analyst information

At 09:00 CET today, the management hosts a webcast. The webcasted presentation
will be in English. To join, please use the link that is available at
www.akerbiomarine.com/investor. 

A replay of the presentation will be made available soon after the presentation
at the same web address.

For further information, please contact 
Christopher Robin Vinter, VP Strategic Finance & IR 
Mobile: +47 911 60 820 
Email:  Christopher.vinter@akerbiomarine.com  

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops
krill-derived products for consumer health and nutrition. Krill is a natural,
powerful, and health-promoting source of nutrients from the pristine waters of
Antarctica, and Aker BioMarine has a unique position in its industry. The
ingredient portfolio consists of Superba Krill Oil, Lysoveta, FloraMarine, and
PL+, as well as the consumer brand, Kori Krill. The innovative approach also
extends into the spin-offs AION (reduce and recycle plastic waste across
industries) and Understory (a protein brand). Aker BioMarine is listed on the
Oslo Stock Exchange (AKBM). More information is available at
www.akerbiomarine.com.